Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930

CAMBRIDGE, Mass., June 12, 2018 (GLOBE NEWSWIRE) — Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company …
(Orginal – Story lesen…)





auch interessant